Benjamin, David J. http://orcid.org/0000-0002-2392-886X
Shrestha, Anshu
Fellman, Dimitra
Cress, Rosemary D.
Lythgoe, Mark P. http://orcid.org/0000-0002-8952-7639
Rezazadeh Kalebasty, Arash
Article History
Received: 14 April 2023
Revised: 13 September 2023
Accepted: 27 September 2023
First Online: 5 October 2023
Change Date: 14 November 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41391-023-00749-0
Competing interests
: ARK has the following disclosures: Stock and Other Ownership Interests: ECOM Medical. Consulting or Advisory Role: Exelixis, AstraZeneca, Bayer, Pfizer, Novartis, Genentech, Bristol Myers Squibb, EMD Serono, Immunomedics, Gilead Sciences. Speakers’ Bureau: Janssen, Astellas Medivation, Pfizer, Novartis, Sanofi, Genentech/Roche, Eisai, AstraZeneca, Bristol Myers Squibb, Amgen, Exelixis, EMD Serono, Merck, Seattle Genetics/Astellas, Myovant Sciences, Gilead Sciences, AVEO. Research Funding: Genentech, Exelixis, Janssen, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Macrogenics, Astellas Pharma, BeyondSpring Pharmaceuticals, BioClin Therapeutics, Clovis Oncology, Bavarian Nordic, Seattle Genetics, Immunomedics, Epizyme. Travel, Accommodations, Expenses: Genentech, Prometheus, Astellas Medivation, Janssen, Eisai, Bayer, Pfizer, Novartis, Exelixis, AstraZeneca. DJB has received consulting fees from Seagen. MPL has received advisory fees from Clovis Oncology. The remaining authors (AS, DF, and RDC) have no disclosures.